All Outputs (6)

Urine biomarkers for the early detection of ovarian cancer – are we there yet? (2019)
Journal Article
Grayson, K., Gregory, E., Khan, G., & Guinn, B.-A. (2019). Urine biomarkers for the early detection of ovarian cancer – are we there yet?. Biomarkers in Cancer, 11, Article 1983097. https://doi.org/10.1177/1179299x19830977

Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; ho... Read More about Urine biomarkers for the early detection of ovarian cancer – are we there yet?.

Antigenic targets for the immunotherapy of acute myeloid leukaemia (2019)
Journal Article
Khan, G., Orchard, K., & Guinn, B. A. (2019). Antigenic targets for the immunotherapy of acute myeloid leukaemia. Journal of Clinical Medicine, 8(2), 134. https://doi.org/10.3390/jcm8020134

One of the most promising approaches to preventing relapse is the stimulation of the body’s own immune system to kill residual cancer cells after conventional therapy has destroyed the bulk of the tumour. In acute myeloid leukaemia (AML), the high fr... Read More about Antigenic targets for the immunotherapy of acute myeloid leukaemia.

Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis (2015)
Journal Article
Brooks, S. E., Bonney, S. A., Lee, C., Publicover, A., Khan, G., Smits, E. L., Sigurdardottir, D., Arno, M., Li, D., Mills, K. I., Pulford, K., Banham, A. H., Van Tendeloo, V., Mufti, G. J., Rammensee, H. G., Elliott, T. J., Orchard, K. H., & Guinn, B. A. (2015). Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. PLoS ONE, 10(10), Article e0140483. https://doi.org/10.1371/journal.pone.0140483

Immunotherapy treatments for cancer are becoming increasingly successful, however to further improve our understanding of the T-cell recognition involved in effective responses and to encourage moves towards the development of personalised treatments... Read More about Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis.

Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer (2015)
Journal Article
Khan, G., Brooks, S. E., Mills, K. I., & Guinn, B.-A. (2015). Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer. Biomarkers in Cancer, 7, 31–38. https://doi.org/10.4137/bic.s28378

Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Ther... Read More about Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer.

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies (2013)
Journal Article
Khan, G., Denniss, F., Mills, K. I., Guinn, B.-A., & Pulford, K. (2013). PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies. Genetic Syndromes and Gene Therapy, 04(09), Article 186. https://doi.org/10.4172/2157-7412.1000186

In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in... Read More about PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies.

An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide (2013)
Journal Article
Hardwick, N., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G., Stevenson, F., & Guinn, B. A. (2013). An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunology Research, 13(3), 16-26. https://doi.org/10.1158/1424-9634.DCL-16.13.3

We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the ca... Read More about An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.